Cargando…
Efficacy of Postoperative FOLFOX Versus XELOX Chemotherapy for Gastric Cancer and Prognostic Value of Platelet–Lymphocyte Ratio in Patients Receiving XELOX
BACKGROUND: Surgery combined with postoperative chemotherapy is an effective method for treating patients with gastric cancer (GC) in Asia. The important roles of systemic inflammatory response in chemotherapy have been gradually verified. The purpose of this study was to assess the difference in cl...
Autores principales: | Yin, Xin, Fang, Tianyi, Wang, Yimin, Li, Chunfeng, Wang, Yufei, Zhang, Daoxu, Xue, Yingwei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7786002/ https://www.ncbi.nlm.nih.gov/pubmed/33425738 http://dx.doi.org/10.3389/fonc.2020.584772 |
Ejemplares similares
-
Peripheral Venous Blood Platelet-to-Lymphocyte Ratio (PLR) for Predicting the Survival of Patients With Gastric Cancer Treated With SOX or XELOX Regimen Neoadjuvant Chemotherapy
por: Chen, Li, et al.
Publicado: (2019) -
Cost-analysis of XELOX and FOLFOX4 for treatment of colorectal cancer to assist decision-making on reimbursement
por: Tse, Vicki C, et al.
Publicado: (2011) -
XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results
por: Cassidy, J, et al.
Publicado: (2011) -
Comparison between hypersensitivity reactions to cycles of modified FOLFOX6 and XELOX therapies in patients with colorectal cancer
por: Ohta, Hideki, et al.
Publicado: (2017) -
Sex-Related Differences in Impact on Safety of Pharmacogenetic Profile for Colon Cancer Patients Treated with FOLFOX-4 or XELOX Adjuvant Chemotherapy
por: Ruzzo, Annamaria, et al.
Publicado: (2019)